We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Empliciti

News List

Empliciti, Revlimid combo falls short in multiple myeloma pharmatimes
March 12, 2020
Bristol-Myers Squibb has revealed that Empliciti (elotuzumab), when added to BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone, has not proved successful in extending the time patients with newly-diagnosed myeloma who were ineligible for ...
US approves new use for BMS’ Empliciti pharmatimes
November 08, 2018
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received
Bristol-Myers, AbbVie net FDA 'breakthrough' for myeloma drug Empliciti fiercepharma
August 27, 2018
The myeloma drug Empliciti is currently approved alongside Revlimid and dexamethasone for patients who have already received anywhere from one to three prior treatments.